Skip to content

Endovascular Denervation in Patients With Cancer Pain

Endovascular Denervation in Patients With Cancer Pain

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03431922
Enrollment
20
Registered
2018-02-13
Start date
2017-09-21
Completion date
2019-09-01
Last updated
2018-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Pain

Brief summary

Endovascular arterial denervation (ED) is a minimally invasive technique which could reduce the occurrence of injury of visceral tissue or organs. As the principle of renal denervation (RDN), Radiofrequency energy delivered by a multi-electrode catheter to the celiac plexus over the anterolateral surface of the superior mesenteric artery (SMA) and the celiac axis. Damaged or partially damaged celiac plexus can achieve the effect of pain relief.

Detailed description

The multi-electrode catheter was consisted of six independent electrodes helically on a net structure, which could be set as the same energy and temperature for simultaneous multi-point ablation. A real-time monitoring capability also provided by the display.

Interventions

multi-electrode catheter-based endovascular denervation

Sponsors

Zhongda Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 25 to 75 years * severe cancer pain with the visual analogue scores of no less than 7

Exclusion criteria

* pregnant or intent to become pregnant within 1 year * postural hypotension * uncorrected coagulation dysfunction * aortic aneurysm or dissection * type 1 diabetes mellitus (T1DM) * acute or severe systemic infection * history of cerebral apoplexy or transient ischemic attack (TIA) in the past two weeks * history of acute coronary syndrome in the past two weeks * participants who are not suitable to be enrolled into the study assessed by the researchers

Design outcomes

Primary

MeasureTime frameDescription
Pain relieffrom baseline to 1 months after procedureChanges of the visual analogue scores (VAS) scores

Secondary

MeasureTime frameDescription
Pain relieffrom baseline to 3 months after procedureChanges of the visual analogue scores (VAS) scores
Improvement of Quality of Lifefrom baseline to 3 months after procedureChanges of the 100-item World Health Organization Quality of Life (QOL)
Incidence of Treatment Adverse Eventsfrom baseline to 1 months after procedureAssess artery damage, such as abdominal aortic dissection and abdominal aneurysm, by digital subtraction angiography or computed tomography

Countries

China

Contacts

Primary ContactGao-Jun Teng, MD
gjteng@seu.edu.cn+86 25 83272121
Backup ContactQi Zhang, PhD
dnzhangqi@126.com+86-15312027895

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026